PPIB and injury: The first member of the cyclophilins to be identified in mammals, cyclophilin A, is the major cellular target for the immunosuppressive drug cyclosporin A (CsA) as well as newly developed small molecule analogs of CsA that have been shown to limit inflammation and injury by inhibiting neutrophilia in a model of LPS induced acute lung injury [63].